Patton, John T <br/><br/>
The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease.  [electronic resource] 

 -  Oncotarget  Feb 2015 
 - 2693-708 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.2098  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adaptive Immunity--drug effects<br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>CD8-Positive T-Lymphocytes--drug effects<br/>Cells, Cultured<br/>Coculture Techniques<br/>Cytotoxicity, Immunologic--drug effects<br/>Epstein-Barr Virus Infections--drug therapy<br/>Herpesvirus 4, Human--drug effects<br/>Immunity, Innate--drug effects<br/>Lymphocytes, Tumor-Infiltrating--drug effects<br/>Lymphoproliferative Disorders--drug therapy<br/>Mice, SCID<br/>Protein Biosynthesis--drug effects<br/>Proto-Oncogene Proteins c-akt--metabolism<br/>STAT1 Transcription Factor--metabolism<br/>STAT3 Transcription Factor--metabolism<br/>Signal Transduction--drug effects<br/>Time Factors<br/>Triterpenes--pharmacology<br/>Viral Matrix Proteins--metabolism